Can-Fite BioPharma (CANF) Shares Outstanding (2013 - 2025)
Can-Fite BioPharma's (CANF) quarterly Shares Outstanding (Entity) came in at $1.3 million in Q4 2025, up 116.58% YoY from $612618.0 in Q4 2024, and up 76.76% on a QoQ basis from $750620.0 in Q2 2025.
Can-Fite BioPharma (CANF) Shares Outstanding (2013 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 12 years of Shares Outstanding (Entity) data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 116.58% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (up 116.58% YoY) and the FY2025 annual result came in at $1.3 million, up 116.58% from the prior year.
- Shares Outstanding (Entity) rose to $1.3 million in Q4 2025, from $750620.0 in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $1.3 million in Q4 2025 to a low of $10646.0 in Q1 2021.
- A 5-year average of $288146.5 and a median of $219408.0 in 2022 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) soared 1383.09% — and 2024, when it soared 43.95%.
- Tracing CANF's Shares Outstanding (Entity) over 5 years: stood at $12168.0 in 2021, then jumped by 1374.88% to $179464.0 in 2022, then soared by 137.14% to $425587.0 in 2023, then surged by 43.95% to $612618.0 in 2024, then surged by 116.58% to $1.3 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $1.3 million (Q4 2025), $750620.0 (Q2 2025), and $612618.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | 823,104.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.65 Mn |
| Jun 30, 2025 | 22.52 Mn |
| Dec 31, 2024 | 18.38 Mn |
| Jun 30, 2024 | 12.79 Mn |
| Dec 31, 2023 | 12.77 Mn |
| Sep 30, 2023 | 7.98 Mn |
| Jun 30, 2023 | 7.93 Mn |
| Mar 31, 2023 | 7.78 Mn |
| Dec 31, 2022 | 5.38 Mn |
| Sep 30, 2022 | 538,393.00 |
| Jun 30, 2022 | 538,393.00 |
| Mar 31, 2022 | 538,393.00 |
| Dec 31, 2021 | 365,033.00 |
| Sep 30, 2021 | 340,506.00 |
| Jun 30, 2021 | 330,007.00 |
| Mar 31, 2021 | 319,387.00 |
| Dec 31, 2020 | 236,551.00 |
| Sep 30, 2020 | 213,418.00 |
| Jun 30, 2020 | 168,261.00 |
| Mar 31, 2020 | 132,946.00 |